(Go: >> BACK << -|- >> HOME <<)
Jump to content

Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
PotatoBot (talk | contribs)
Bots
51,239 edits
m Stub sorting and placement of stub template(s): monoclonal-antibody-, antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.
→‎top: infobox, description
 
(23 intermediate revisions by 16 users not shown)
Line 1: Line 1:
⚫
{{Short description|Monoclonal antibody}}
{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan}}
{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
⚫
| verifiedrevid = 400279804
| Watchedfields = changed
⚫
| verifiedrevid = 470635003
| image = Y-90 tacatuzumab tetraxetan structure.svg
| image = Y-90 tacatuzumab tetraxetan structure.svg
| drug_name = Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan
| drug_name = Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan
<!-- Monoclonal antibody data -->

⚫
<!--Monoclonal antibody data-->
| type = mab
| type = mab
| mab_type = mab
| mab_type = mab
| source = zu/o
| source = zu/o
| target = [[α-fetoprotein]]
| target = [[α-fetoprotein]]
⚫
<!-- Clinical data -->

| tradename =
⚫
<!--Clinical data-->
| tradename =
| pregnancy_AU =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_US =
| pregnancy_category =
| pregnancy_category =
| legal_AU =
| legal_AU =
| legal_CA =
| legal_CA =
| legal_UK =
| legal_UK =
| legal_US =
| legal_US =
| legal_status =
⚫
| routes_of_administration =
| legal_status =
⚫
<!-- Pharmacokinetic data -->
⚫
| routes_of_administration =
| bioavailability =

⚫
| protein_bound =
⚫
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
⚫
| elimination_half-life =
⚫
| protein_bound =
| metabolism =
| excretion =
⚫
<!-- Identifiers -->
⚫
| elimination_half-life =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| excretion =
| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}
⚫
<!--Identifiers-->
| CAS_number = 500784-58-7
| CAS_number = 476413-07-7
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GJ2416WK6Y
| ATC_prefix = none
| ATC_prefix = none
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =

<!--Chemical data-->
<!-- Chemical data -->
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y
⚫
| molecular_weight = 145

| molecular_weight_comment = kg/mol
⚫
| molecular_weight = 145 [[kDa]]
}}
}}


'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' (trade name '''AFP-Cide''') is a [[humanize]]d [[monoclonal antibody]] intended for the treatment of cancer.<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc Statement On A Nonproprietary Name Adopted By The USAN Counil]</ref> The antibody itself, tacatuzumab, is conjugated with a [[chelator]] for [[yttrium-90]]<ref>[http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref>, a [[radioisotope]] which destroys the tumour cells.
'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' is an investigational [[humanized monoclonal antibody]] intended for the treatment of cancer.<ref>{{cite web|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc|url-status=dead|archive-url=https://web.archive.org/web/20040911162110/http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc|date=4 September 2004 |title=Statement On A Nonproprietary Name Adopted By The USAN Council|archive-date=2004-09-11 }}</ref> The antibody itself, tacatuzumab, is conjugated with [[tetraxetan]], a [[chelator]] for [[yttrium-90]],<ref>[https://web.archive.org/web/20110705093023/http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref> a [[radioisotope]] which destroys the tumour cells.

The chelator ("tetraxetan") is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The antibody is attached to one of the four carboxyl groups as an [[amide]], and the other three are [[carboxylate anion]]s neutralizing the three positive charges of the yttrium ion.


==References==
==References==
Line 54: Line 56:
{{DEFAULTSORT:Yttrium Tacatuzumab Tetraxetan}}
{{DEFAULTSORT:Yttrium Tacatuzumab Tetraxetan}}
[[Category:Monoclonal antibodies for tumors]]
[[Category:Monoclonal antibodies for tumors]]
[[Category:Antibody-drug conjugates]]
[[Category:Radiopharmaceuticals]]
[[Category:Yttrium compounds]]
[[Category:Experimental cancer drugs]]
[[Category:DOTA (chelator) derivatives]]




{{monoclonal-antibody-stub}}
{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}
{{antineoplastic-drug-stub}}
{{nuclear-med-stub}}

[[it:Tacatuzumab tetraxetan]]

Latest revision as of 06:30, 31 December 2023

Yttrium (90Y) tacatuzumab tetraxetan
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetα-fetoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9971N1712O2007S4290Y
Molar mass145 kg/mol
 ☒NcheckY (what is this?)  (verify)

Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
  2. ^ WHO Drug Information


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This nuclear medicine article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Yttrium_(90Y)_tacatuzumab_tetraxetan&oldid=1192770004"